| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Mutant KRAS is a druggable target for pancreatic cancer. | Proc Natl Acad Sci U S A | 2013 | 1.26 |
| 2 | Parametric diffusion tensor imaging of the breast. | Invest Radiol | 2012 | 0.94 |
| 3 | The founder Ashkenazi Jewish mutations in the MSH2 and MSH6 genes in Israeli patients with gastric and pancreatic cancer. | Fam Cancer | 2012 | 0.78 |
| 4 | Chimeric molecule IL-6/soluble IL-6 receptor is a potent mitogen for fetal hepatocytes. | J Cell Physiol | 2004 | 0.75 |
| 5 | Cetuximab in metastatic colorectal cancer. | Lancet Oncol | 2010 | 0.75 |
| 6 | [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin]. | Harefuah | 2014 | 0.75 |